Ittai Harel

Managing General Partner at Pitango Venture Capital

Ittai Harel is a prominent figure in the health technology sector, currently serving as a Board Member at 8400 The Health Network. He is also the Managing General Partner at Pitango Venture Capital, a role he has held since July 2006, where he focuses on investments in digital health, medical devices, diagnostics, and therapeutic development companies. Harel has extensive experience in advising and assisting entrepreneurs and management teams in the growth of their companies.1 3

Professional Background

8400 The Health Network: Board Member, contributing to initiatives that support HealthTech startups.
Pitango Venture Capital: Managing General Partner, leading investments and strategic guidance in the health sector.
Board Positions: Harel holds various director roles on the boards of multiple companies, including:
- QuantHealth (2023 - Present)
- Protai (2022 - Present)
- Connie Health (2021 - Present)
- ImmuneID (2021 - Present)
- Homethrive, Inc (2020 - Present)
- Medisafe® (2015 - Present)
- DouxMatok (2017 - Present) among others.1 2 3

Education

Harel holds a Bachelor of Science in Chemical Engineering and Biotechnology from Ben-Gurion University of the Negev (1989-1993) and a Master of Science in Management and Marketing from the MIT Sloan School of Management (1993-1995)【2】.

His extensive background in both entrepreneurship and investment positions him as a key player in advancing health technology innovations.

Experience

Managing General Partner at Pitango Venture Capital (July 2006 - Present)

Director Board of Directors at QuantHealth (January 2023 - Present), Protai (January 2022 - Present), Connie Health (April 2021 - Present), ImmuneID (January 2021 - Present), Homethrive, Inc (October 2020 - Present), Visby Medical (Observer, November 2018 - Present), DouxMatok (July 2017 - Present), CLEW (January 2017 - Present), Medisafe® Medication Adherence Platform (January 2015 - Present), Vertos Medical Inc (September 2013 - Present), Chairman of the Board of Directors at EarlySense (August 2010 - July 2022), Chairman of the Board of Directors at LifeBond Ltd. (June 2009 - January 2020), Member of the Board of Directors at Inotek Pharmaceuticals (November 2010 - July 2016), Member of the Board of Directors at Valeritas (September 2008 - March 2016), Corporate Development at Nektar Therapeutics (February 2002 - June 2006), Exec VP, Corporate Development at IDGene Pharmaceuticals (April 2000 - February 2002), Marketing, Business Development, and General Management at IDEXX Laboratories (May 1994 - April 2000)

Education

M.Sc. in Management and Marketing from MIT Sloan School of Management (1993 - 1995), B.Sc. in Chemical Engineering and Biotechnology from Ben-Gurion University of the Negev (1989 - 1993)